Skip to main content
Journal cover image

Public reporting of black participation in anti-hypertensive drug clinical trials.

Publication ,  Journal Article
Green, MD; Dalmage, MR; Lusk, JB; Kadhim, EF; Skalla, LA; O'Brien, EC
Published in: Am Heart J
April 2023

BACKGROUND: Non-Hispanic Black people in the United States have the highest prevalence of essential hypertension. Unfortunately, clinical trials often underrepresent Black patients. We aim to understand whether trial sponsorship type is associated with representation of Black participants in anti-hypertensive drug clinical trials. Then, we contextualize our findings amongst current efforts to improve diversity in clinical research populations. METHODS: We searched ClinicalTrials.gov in May 2022 for antihypertensive drug trials. Of n = 408 trials in our initial search, n = 97 (23.77%) met inclusion criteria and were stratified by sponsorship type (industry vs non-industry). Standardized tests of difference were employed to compare characteristics of these trials, and linear regression was used to model change over time. RESULTS: Of 97 trials reporting results from 2010 to 2020, there were minimal differences in the percent of Black patients enrolled in anti-hypertensive clinical trials by sponsorship type. Both industry and non-industry sponsored studies had high rates of non-reporting, with slightly more non-reporting for industry (73.2%) vs non-industry (66.67%) studies. Industry funded studies reported results to ClinicalTrials.gov within 23.3 ± 15.0 months from completing studies, while non-industry funded trials reported within 18.9 ± 10.8 months. CONCLUSIONS: Despite Black Americans carrying the highest burden of disease for essential hypertension, they are underrepresented in anti-hypertension clinical trials and their overall participation has decreased between 2010 and 2020. In addition, there is major underreporting of trial participant race. We implore researchers and funders to establish clear, meaningful targets for anti-hypertensive drug trial diversity, and improve transparency in reporting of study characteristics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

April 2023

Volume

258

Start / End Page

129 / 139

Location

United States

Related Subject Headings

  • United States
  • Patient Participation
  • Humans
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Black or African American
  • Antihypertensive Agents
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Green, M. D., Dalmage, M. R., Lusk, J. B., Kadhim, E. F., Skalla, L. A., & O’Brien, E. C. (2023). Public reporting of black participation in anti-hypertensive drug clinical trials. Am Heart J, 258, 129–139. https://doi.org/10.1016/j.ahj.2023.01.001
Green, Michael D., Mahalia R. Dalmage, Jay B. Lusk, Emilie F. Kadhim, Lesley A. Skalla, and Emily C. O’Brien. “Public reporting of black participation in anti-hypertensive drug clinical trials.Am Heart J 258 (April 2023): 129–39. https://doi.org/10.1016/j.ahj.2023.01.001.
Green MD, Dalmage MR, Lusk JB, Kadhim EF, Skalla LA, O’Brien EC. Public reporting of black participation in anti-hypertensive drug clinical trials. Am Heart J. 2023 Apr;258:129–39.
Green, Michael D., et al. “Public reporting of black participation in anti-hypertensive drug clinical trials.Am Heart J, vol. 258, Apr. 2023, pp. 129–39. Pubmed, doi:10.1016/j.ahj.2023.01.001.
Green MD, Dalmage MR, Lusk JB, Kadhim EF, Skalla LA, O’Brien EC. Public reporting of black participation in anti-hypertensive drug clinical trials. Am Heart J. 2023 Apr;258:129–139.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

April 2023

Volume

258

Start / End Page

129 / 139

Location

United States

Related Subject Headings

  • United States
  • Patient Participation
  • Humans
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Black or African American
  • Antihypertensive Agents
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology